The Latest Drugs in Development That Reduce Intraocular Pressure in Ocular Hypertension and Glaucoma

References

• Kass MA, Heuer DK, Higginbotham EJ, et al. The ocular hypertension treatment study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthal. 2002;120(6):701–713. doi:10.1001/archopht.120.6.701
   PubMed Web of Science ®Google Scholar
• Medeiros FA, Weinreb RN, Sample PA, et al. Validation of a predictive model to estimate the risk of conversion from ocular hypertension to glaucoma. Arch Ophthal. 2005;123(10):1351–1360. doi:10.1001/archopht.123.10.1351
   Google Scholar
• Johnson M, McLaren JW, Overby DR. Unconventional aqueous humor outflow: a review. Exp Eye Res. 2017;158:94–111. doi:10.1016/j.exer.2016.01.017
   PubMed Web of Science ®Google Scholar
• Gordon MO, Beiser JA, Brandt JD, et al. The ocular hypertension treatment study: baseline factors that predict the onset of primary open-angle glaucoma. Arch Ophthal. 2002;120(6):714–720. doi:10.1001/archopht.120.6.714
   PubMedGoogle Scholar
• Cantor LB. Brimonidine in the treatment of glaucoma and ocular hypertension. Ther Clin Risk Manag. 2006;2(4):337.
   PubMedGoogle Scholar
• Reitsamer HA, Posey M, Kiel JW. Effects of a topical α2 adrenergic agonist on ciliary blood flow and aqueous production in rabbits. Exp Eye Res. 2006;82(3):405–415. doi:10.1016/j.exer.2005.07.015
   Web of Science ®Google Scholar
• Zimmerman TJ. Topical ophthalmic beta blockers: a comparative review. J Ocul Pharmacol Ther. 1993;9(4):373–384. doi:10.1089/jop.1993.9.373
   Web of Science ®Google Scholar
• Maren TH. Carbonic anhydrase: general perspective and advances in glaucoma research. Drug Dev Res. 1987;10(4):255–276. doi:10.1002/ddr.430100407
   Web of Science ®Google Scholar
• Farzam K, Abdullah M. Acetazolamide. StatPearls [Internet]. StatPearls Publishing; 2019.
   Google Scholar
• Katayama F, Miura H, Takanashi S. Long-term effectiveness and side effects of acetazolamide as an adjunct to other anticonvulsants in the treatment of refractory epilepsies. Brain Dev. 2002;24(3):150–154. doi:10.1016/S0387-7604(02)00003-7
   Web of Science ®Google Scholar
• Cantor LB. The evolving pharmacotherapeutic profile of brimonidine, an 2-adrenergic agonist, after four years of continuous use. Expert Opin Pharmacother. 2000;1(4):815–834. doi:10.1517/14656566.1.4.815
   PubMedGoogle Scholar
• Bowman RJC, Cope J, Nischal KK. Ocular and systemic side effects of brimonidine 0.2% eye drops (Alphagan®) in children. Eye. 2004;18(1):24–26. doi:10.1038/sj.eye.6700520
   PubMed Web of Science ®Google Scholar
• Scahill L. Alpha-2 adrenergic agonists in children with inattention, hyperactivity and impulsiveness. CNS Drugs. 2009;23(Supplement 1):43–49. doi:10.2165/00023210-200923000-00006
   Web of Science ®Google Scholar
• Stamer WD, Piwnica D, Jolas T, et al. Cellular basis for bimatoprost effects on human conventional outflow. Invest Ophthal. 2010;51(10):5176–5181. doi:10.1167/iovs.09-4955
   Google Scholar
• Oh DJ, Martin JL, Williams AJ, et al. Analysis of expression of matrix metalloproteinases and tissue inhibitors of metalloproteinases in human ciliary body after latanoprost. Invest Ophthal. 2006;47(3):953–963. doi:10.1167/iovs.05-0516
   Google Scholar
• Holló G. The side effects of the prostaglandin analogues. Expert Opin Drug Saf. 2007;6(1):45–52. doi:10.1517/14740338.6.1.45
   PubMed Web of Science ®Google Scholar
• Alm A, Grierson I, Shields MB. Side effects associated with prostaglandin analog therapy. Surv Ophthalmol. 2008;53(Suppl1):S93–105. doi:10.1016/j.survophthal.2008.08.004
   Web of Science ®Google Scholar
• Khaw PT, Shah P, Elkington AR. Glaucoma—2:Treatment. BMJ. 2004;328(7432):156–158. doi:10.1136/bmj.328.7432.156
   Web of Science ®Google Scholar
• Skaat A, Rosman MS, Chien JL. Effect of pilocarpine hydrochloride on the Schlemm canal in healthy eyes and eyes with open-angle glaucoma. JAMA Ophthal. 2016;134(9):976–981. doi:10.1001/jamaophthalmol.2016.1881
   Web of Science ®Google Scholar
• Puustjärvi T. Retinal detachment during glaucoma therapy. Ophthalmologica. 1985;190(1):40–44. doi:10.1159/000309490
   Web of Science ®Google Scholar
• Singh M. Miotic-induced retinal detachment: a case report. Med J Malaysia. 1985;40(2).
   Google Scholar
• Kinney M, Johnson A, Reddix M, McCann MB. Temporal effects of 2% pilocarpine ophthalmic solution on human pupil size and accommodation. Mil Med. 2020;185(Supplement_1):435–442. doi:10.1093/milmed/usz235
   Web of Science ®Google Scholar
• Honjo M, Inatani M, Kido N, et al. Effects of protein kinase inhibitor, HA1077, on intraocular pressure and outflow facility in rabbit eyes. Arch Ophthal. 2001;119(8):1171–1178. doi:10.1001/archopht.119.8.1171
   PubMed Web of Science ®Google Scholar
• Honjo M, Hidenobu T, Inatani M, et al. Effects of rho-associated protein kinase inhibitor Y-27632 on intraocular pressure and outflow facility. Invest Ophthal. 2001;42(1):137–144.
   Google Scholar
• Rao PV, Deng P, Kumar J, Epstein DL. Modulation of aqueous humor outflow facility by the Rho kinase–specific inhibitor Y-27632. Invest Ophthal. 2001;42(5):1029–1037.
   Google Scholar
• Tanna AP, Johnson M. Rho kinase inhibitors as a novel treatment for glaucoma and ocular hypertension. Ophthalmology. 2018;125(11):1741–1756. doi:10.1016/j.ophtha.2018.04.040
   PubMed Web of Science ®Google Scholar
• Okeke C, Cooper MS, Brinkley D, Deom J, Thimons J. Latanoprostene bunod ophthalmic solution 0.024% in patients with glaucoma or ocular hypertension new to pharmacotherapy. Invest Ophthal. 2020;61(7):4260.
   Google Scholar
• Sharma H, Radell KE, Gagliuoso D, Chadha N, Tsai JC, Serle J. First year real world clinical experience with latanoprostene bunod. Invest Ophthal. 2020;61(7):1244.
   Google Scholar
• Tsai JC, McClure CA, Ramos SE, Schlundt DG, Pichert JW. Compliance barriers in glaucoma: a systematic classification. J Glaucoma. 2003;12(5):393–398. doi:10.1097/00061198-200310000-00001
   PubMed Web of Science ®Google Scholar
• Doucette LP, Walter MA. Prostaglandins in the eye: function, expression, and roles in glaucoma. Ophthalmic Genet. 2017;38(2):108–116. doi:10.3109/13816810.2016.1164193
   PubMed Web of Science ®Google Scholar
• van der Valk R, Webers CAB, Schouten JSAG, Zeegers MP, Hendrikse F, Prinz MH. Intraocular pressure–lowering effects of all commonly used glaucoma drugs: a meta-analysis of randomized clinical trials. Ophthalmology. 2005;112(7):1177–1185. doi:10.1016/j.ophtha.2005.01.042
   PubMed Web of Science ®Google Scholar
• Inman S, Wirta DL Sepetaprost is safe, effective for IOP reduction in POAH and OHT. HCP Live Conference Coverage; 2019. Available from: https://www.mdmag.com/conference-coverage/aao-2019/sepetaprost-safe-effective-for-iop-reduction-in-poah-and-oht. Accessed May 12, 2020.
   Google Scholar
• Sharif NA, Kirihara T, Iwamura R, et al. A novel non-prostaglandin EP2-receptor agonist for glaucoma treatment: omidenepag isopropyl (DE-117). FASEB J. 2020;34(S1):1. doi:10.1096/fasebj.2020.34.s1.08817
   Web of Science ®Google Scholar
• Lu F, Aihara M, Kawata H, Iwata A, Odani-Kawabata N, Shams NK. A phase 3 trial comparing omidenepag isopropyl 0.002% with latanoprost 0.005% in primary open-angle glaucoma and ocular hypertension: the AYAME study. Invest Ophthal. 2018;59(9):1235.
   Google Scholar
• Aihara M, Lu F, Kawata H, et al. Phase 2, randomized, dose-finding studies of omidenepag isopropyl, a selective EP2 agonist, in patients with primary open-angle glaucoma or ocular hypertension. J Glaucoma. 2019;28(5):375–385. doi:10.1097/IJG.0000000000001221
   PubMed Web of Science ®Google Scholar
• Dismuke WM, Liang J, Overby DR, Stamer WD. Concentration-related effects of nitric oxide and endothelin-1 on human trabecular meshwork cell contractility. Exp Eye Res. 2014;120:28–35. doi:10.1016/j.exer.2013.12.012
   PubMed Web of Science ®Google Scholar
• de Kater AW, Spurr-Michaud SJ, Gipson IK. Localization of smooth muscle myosin-containing cells in the aqueous outflow pathway. Invest Ophthal. 1990;31(2):347–353.
   Google Scholar
• Impagnatiello F, Toris CB, Batugo M, et al. Intraocular pressure–lowering activity of NCX 470, a novel nitric oxide–donating bimatoprost in preclinical models. Invest Ophthal. 2015;56(11):6558–6564. doi:10.1167/iovs.15-17190
   Google Scholar
• businesswire [page on the internet] businesswire. A Berkshire Hathaway company: ocuphire pharma announces results from two phase 2 clinical studies of nyxol eye drops; 2019. Available from: https://www.businesswire.com/news/home/20191107005535/en/Ocuphire-Pharma-Announces-Results-Phase-2-Clinical#:~:text=Drops%20%7C%20Business%20Wire-,Ocuphire%20Pharma%20Announces%20Results%20from%20Two%20Phase%202,of%20Nyxol%C2%AE%20Eye%20Drops&text=FARMINGTON%20HILLS%2C%20Mich.&text=Results%20included%20a%20clear%20improvement,both%20acute%20and%20chronic%20settings. Accessed May 13, 2020.
   Google Scholar
• Peters K; for Aerpio Pharmaceuticals Inc. AKB-9778: a Novel Approach to Glaucoma Treatment Targeting Tie2 in the Conventional Outflow Pathway. Proceedings of the Glaucoma 360 New Horizons in Pharmaceuticals Conference. 2020
   Google Scholar
• Hidaka H, Sumi K, Izuhara T, Kasai A, Tanimoto H. A novel isoquinoline sulfonamide protein kinase inhibitor (H-1337) produces long-lasting reduction of IOP. Invest Ophthal. 2015;56(7):5712.
   Google Scholar
• dwti.co.jp [webpage on the Internet]. H-1337 (Product Pipeline of D. Western Therapeutics Institute); 2000. Available from: https://www.dwti.co.jp/english/business-outline/product-pipeline/h-1337. Accessed June 21, 2020.
   Google Scholar
• Abbhi V, Piplani P. Rho-kinase (ROCK) inhibitors - a neuroprotective therapeutic paradigm with a focus on ocular utility. Curr Med Chem. 2020;27(14):2222–2256.
   Web of Science ®Google Scholar
• Tokushige H, Inatani M, Nemoto S, et al. Effects of topical administration of y-39983, a selective rho-associated protein kinase inhibitor, on ocular tissues in rabbits and monkeys. Invest Ophthal. 2007;48(7):3216–3222. doi:10.1167/iovs.05-1617
   Google Scholar
• Whitlock NA, Harrison B, Mixon T, et al. Decreased intraocular pressure in mice following either pharmacological or genetic inhibition of ROCK. J Ocul Pharmacol Ther. 2009;25(3):187–194. doi:10.1089/jop.2008.0142
   Web of Science ®Google Scholar
• Tanihara H, Masaru I, Honho M, Tokushige H, Azuma J, Araie M. Intraocular pressure–lowering effects and safety of topical administration of a selective ROCK inhibitor, SNJ-1656, in healthy volunteers. Arch Ophthal. 2008;126(3):309–315. doi:10.1001/archophthalmol.2007.76
   PubMedGoogle Scholar
• Inoue T, Tanihara H, Tokushige H, Araie M. Efficacy and safety of SNJ-1656 in primary open-angle glaucoma or ocular hypertension. Acta Ophthalmol. 2015;93(5):e393–e395. doi:10.1111/aos.12641
   PubMed Web of Science ®Google Scholar
• aao.org [webpage on the Internet]; Karmel M. Glaucoma pipeline drugs: targeting the trabecular meshwork. EyeNet Magazine; 2013. Available from https://www.aao.org/eyenet/article/glaucoma-pipeline-drugs-targeting-trabecular-meshw. Accessed June 13, 2020.
   Google Scholar
• PRNewswire [Webpage]. Amakem therapeutics presents positive top-line clinical results for AMA0076 for glaucoma at ophthalmology innovation summit. Proceedings of the ophthalmology innovation summit; 2013. Diepenbeek, Belgium. PR Newswire. Available from https://www.prnewswire.com/news-releases/amakem-presents-positive-top-line-clinical-results-for-ama0076-for-glaucoma-at-ophthalmology-innovation-summit-231913301.html. Accessed June 21, 2020.
   Google Scholar
• pH-pharma.com [webpage on the Internet]. pH pharma proprietary pipeline: PHP-201; 2018. Available from http://www.ph-pharma.com/en/portfolio/page01.html#PHP201. Accessed June 21, 2020.
   Google Scholar
• Hsu C, Chen Y, Liu C, et al. A highly selective Rho-kinase inhibitor (ITRI-E-212) potentially treats glaucoma upon topical administration with low incidence of ocular hyperemia. Invest Ophthal. 2019;60(2):624–633. doi:10.1167/iovs.18-25252
   Google Scholar
• Martin P, Cohen A, Uddin S, Epelbaum L, Josiah S. Randomized, double-masked, placebo-controlled dose escalation study of TAK-639 topical ophthalmic solution in subjects with ocular hypertension or primary open-angle glaucoma. Clin Ophthal. 2020;14:885. doi:10.2147/OPTH.S242932
   Web of Science ®Google Scholar
• Savinainen A, Prusakiewicz JJ, Oswald J, et al. Pharmacokinetics and intraocular pressure–lowering activity of TAK-639, a novel C-type natriuretic peptide analog, in rabbit, dog, and monkey. Exp Eye Res. 2019;189:107836. doi:10.1016/j.exer.2019.107836
   PubMed Web of Science ®Google Scholar
• Gupta SK, Agarwal R, Galpalli ND, Srivastava S, Agrawal SS, Saxena R. Comparative efficacy of pilocarpine, timolol and latanoprost in experimental models of glaucoma. Methods Find Exp Clin Pharmacol. 2007;29(10):665–672. doi:10.1358/mf.2007.29.10.1147765
   PubMedGoogle Scholar
• Martínez T, González MV, Roehl I, Wright N, Pañeda C, Jiménez AI. In vitro and in vivo efficacy of SYL040012, a novel siRNA compound for treatment of glaucoma. Mol Ther. 2014;22(1):81–91.
   PubMed Web of Science ®Google Scholar
• Sylentis.com [webpage on the Internet]. R&D products: bamosiran. Sylentis; 2020. Available from https://www.sylentis.com/index.php/en/pipeline/bamosiran. Accessed June 21, 2020.
   Google Scholar
• Lu LJ, Tsai JC, Liu J. Focus: drug development: novel pharmacologic candidates for treatment of primary open-angle glaucoma. Yale J Biol Med. 2017;90(1):111.
   PubMed Web of Science ®Google Scholar
• Park C, Han C, Sakaguchi Y, Lee J, Youn H. Safety evaluation of FM101, an A3 adenosine receptor modulator, in rat, for developing as therapeutics of glaucoma and hepatitis. EXCLI J. 2020;19:187.
   Web of Science ®Google Scholar
• worldglaucoma.net [webpage on the Internet]; Lee S, Yang J, Park C, Lee H, Lee M. Efficacy, pharmacokinetic and non-clinical safety profile of a novel A3AR antagonist, FM101, in the treatment of glaucoma by oral administration; 2017. Available from: https://wga.one/WGC/2017/wgc2017_thefiles/uploads/ninja-forms/6/2017%20WGC%20-%20Poster-Final.pdf. Accessed September 29, 2020.
   Google Scholar
• Ciolino JB, Ross AE, Tulsan R, et al. Latanoprost-eluting contact lenses in glaucomatous monkeys. Ophthalmology. 2016;123(10):2085–2092. doi:10.1016/j.ophtha.2016.06.038
   PubMed Web of Science ®Google Scholar
• Shalaby WS, Shankar V, Razeghinejad R, Katz LJ. Current and new pharmacotherapeutic approaches for glaucoma. Expert Opin Pharmacother. 2020;1–14. doi:10.1080/14656566.2020.1795130
   Web of Science ®Google Scholar
• Hennessy AL, Katz J, Covert D, Protzko C, Robin AL. Videotaped evaluation of eyedrop instillation in glaucoma patients with visual impairment or moderate to severe visual field loss. Ophthalmology. 2010;117(12):2345–2352. doi:10.1016/j.ophtha.2010.03.040
   PubMed Web of Science ®Google Scholar
• Glaukos. Glaukos corporation’s idose™ travaprost achieves sustained IOP reduction and favorable safety profile in 12-month interim cohort; 2018. Available from: http://investors.glaukos.com/investors/press-releases/press-release-details/2018/Glaukos-Corporations-iDose-Travoprost-Achieves-Sustained-IOP-Reduction-and-Favorable-Safety-Profile-in-12-Month-Interim-Cohort/default.aspx. Accessed November 3, 2020.
   Google Scholar
• Craven ER, Walters T, Christie WC, et al. 24-month phase I/II clinical trial of bimatoprost sustained-release implant (Bimatoprost SR) in glaucoma patients. Drugs. 2020;80(2):167–179. doi:10.1007/s40265-019-01248-0
   PubMed Web of Science ®Google Scholar
• Allergen. DurystaTM (bimatoprost implant), for intracameral administration: US prescribing information; 2020. https://media.allergan.com/products/durysta_pi.pdf. Accessed April 20, 2020.
   Google Scholar
• Tanihara H, Inoue T, Yamamoto T, et al. Phase 2 randomized clinical study of a Rho kinase inhibitor, K-115, in primary open-angle glaucoma and ocular hypertension. Am J Ophthal. 2013;156(4):731–736. e732. doi:10.1016/j.ajo.2013.05.016
   PubMed Web of Science ®Google Scholar
• Gazzard G, Konstantakopoulou E, Garway-Heath D, et al. Selective laser trabeculoplasty versus eye drops for first-line treatment of ocular hypertension and glaucoma (LiGHT): a multicentre randomised controlled trial. Lancet. 2019;393(10180):1505–1516.
   PubMed Web of Science ®Google Scholar